Compare Meta Platforms Inc (META) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs BIO-TECHNE Corp — how do they compare? Meta Platforms Inc trades at $647.31 (market cap $1.64T), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Meta Platforms Inc is far larger — about 147× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.45%). Which is the better fit depends on your goals.
| META | TECH | |
|---|---|---|
Market Cap | $1.64T | $11.16B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $72.12 |
52-Week Low | $525.72 | $43.31 |
Enterprise Value | $1.65T | $11.24B |
Dividend Yield | 0.33% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $653.33, up 1.13% in the last session, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected. Revenue grew to $201.0 billion in 2025, with a net income margin of 30.08%. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, driving positive sentiment.
Outlook remains positive with a consensus price target of $817.32, implying 25% upside. Key opportunities include AI monetization and sustained revenue growth, while risks involve regulatory lawsuits and high capital expenditures. Analyst consensus is strongly bullish with 79% buy ratings, but investors should monitor legal developments and competitive pressures in the social media and AI sectors.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
